Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Can Lilly’s Cluster Headache Data Differentiate Its CGRP Inhibitor?

Executive Summary

Galcanezumab was able to reduce episodic cluster headaches compared to placebo, but missed statistical significance for chronic cluster headaches. Amgen’s Aimovig still is first in line to reach the market in the anti-CGRP class.


Related Content

Keeping Track Of Breakthrough Therapy Designations: Depression, Headaches, Hepatitis
Migraine Market Gets Competitive With Second, Third CGRP Inhibitor Launches
Lilly Looks To Emgality Access, Injector And Data To Differentiate Its CGRP Inhibitor
Lilly Looks To Spin Off Animal Health, Focus Cash On Pharma Growth
Teva's CGRP Inhibitor Fails In Chronic Cluster Headaches, Continues In Episodic
As Amgen Looks To Aimovig's Launch, It May Learn From Repatha's Past
Lilly Rides To Solid First Quarter On Diabetes, Newer Products
Bad News Teva Really Doesn't Need: A Potential Delay For Fremanezumab
Lilly Pays Nearly $1bn To Regain Migraine Candidate It Once Sold For $1m
Lilly Shows Off R&D Progress With A Pain Franchise Built On New Mechanisms


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts